Spanish researchers engineered hydrophobic derivatives of resveratrol and oxyresveratrol that demonstrated superior intestinal permeability in Caco-2 cell models and significantly reduced sulfation and glucuronidation—the Phase II metabolic reactions that rapidly clear natural stilbenes from the body. Chemical synthesis proved more efficient than enzymatic methods for creating these modified compounds. This bioengineering approach addresses a fundamental limitation of stilbene supplements: their notorious poor bioavailability despite promising anti-aging and cardioprotective properties in laboratory studies. The modified compounds essentially serve as molecular Trojan horses, bypassing the liver's detoxification machinery that normally renders resveratrol ineffective at typical supplement doses. While resveratrol has generated decades of longevity research interest, human trials have consistently disappointed due to rapid clearance requiring impractical gram-level dosing. These findings suggest a pathway toward clinically relevant stilbene therapeutics, though human pharmacokinetic studies remain necessary. The work represents incremental but meaningful progress in supplement bioengineering, potentially rescuing an entire class of compounds that show promise in vitro but fail in clinical translation.